Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ)
CNY 23.75
(-0.88%)
CNY 23.75
(-0.88%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.76 Billion CNY | -51.33% |
| 2022 | 5.68 Billion CNY | 69.01% |
| 2021 | 3.36 Billion CNY | 19.57% |
| 2020 | 2.81 Billion CNY | 35.64% |
| 2019 | 2.07 Billion CNY | 25.59% |
| 2018 | 1.65 Billion CNY | 44.05% |
| 2017 | 1.14 Billion CNY | 109.28% |
| 2016 | 547.35 Million CNY | 27.65% |
| 2015 | 428.77 Million CNY | 17.35% |
| 2014 | 365.39 Million CNY | 47.55% |
| 2013 | 247.64 Million CNY | 8.92% |
| 2012 | 227.35 Million CNY | 23.95% |
| 2011 | 183.42 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 606.11 Million CNY | -14.88% |
| 2024 Q2 | 712.02 Million CNY | -17.02% |
| 2024 Q1 | 858.05 Million CNY | 12.83% |
| 2023 FY | 2.76 Billion CNY | -51.33% |
| 2023 Q1 | 831.62 Million CNY | -15.49% |
| 2023 Q4 | 760.49 Million CNY | 47.44% |
| 2023 Q2 | 657.01 Million CNY | -21.0% |
| 2023 Q3 | 515.78 Million CNY | -21.5% |
| 2022 Q2 | 1.4 Billion CNY | -46.35% |
| 2022 Q1 | 2.62 Billion CNY | 207.44% |
| 2022 Q4 | 984.1 Million CNY | 48.48% |
| 2022 Q3 | 662.78 Million CNY | -52.94% |
| 2022 FY | 5.68 Billion CNY | 69.01% |
| 2021 Q4 | 853.93 Million CNY | 31.19% |
| 2021 Q1 | 696.6 Million CNY | 9.23% |
| 2021 Q2 | 1.15 Billion CNY | 66.47% |
| 2021 FY | 3.36 Billion CNY | 19.57% |
| 2021 Q3 | 650.89 Million CNY | -43.87% |
| 2020 Q3 | 566.45 Million CNY | -46.3% |
| 2020 Q2 | 1.05 Billion CNY | 91.22% |
| 2020 Q1 | 551.69 Million CNY | -14.89% |
| 2020 FY | 2.81 Billion CNY | 35.64% |
| 2020 Q4 | 637.74 Million CNY | 12.59% |
| 2019 Q3 | 456.27 Million CNY | -11.46% |
| 2019 Q2 | 515.3 Million CNY | 13.88% |
| 2019 FY | 2.07 Billion CNY | 25.59% |
| 2019 Q4 | 648.24 Million CNY | 42.07% |
| 2019 Q1 | 452.49 Million CNY | -8.96% |
| 2018 Q3 | 352.46 Million CNY | -20.97% |
| 2018 Q2 | 446 Million CNY | 25.79% |
| 2018 Q1 | 354.56 Million CNY | -8.84% |
| 2018 FY | 1.65 Billion CNY | 44.05% |
| 2018 Q4 | 497.02 Million CNY | 41.01% |
| 2017 Q4 | 388.92 Million CNY | 26.23% |
| 2017 Q1 | 176.75 Million CNY | 7.78% |
| 2017 Q2 | 271.68 Million CNY | 53.71% |
| 2017 FY | 1.14 Billion CNY | 109.28% |
| 2017 Q3 | 308.11 Million CNY | 13.41% |
| 2016 FY | 547.35 Million CNY | 27.65% |
| 2016 Q4 | 163.99 Million CNY | 21.71% |
| 2016 Q3 | 134.73 Million CNY | -9.03% |
| 2016 Q2 | 148.1 Million CNY | 47.34% |
| 2016 Q1 | 100.51 Million CNY | -29.01% |
| 2015 FY | 428.77 Million CNY | 17.35% |
| 2015 Q4 | 141.58 Million CNY | 48.18% |
| 2015 Q3 | 95.55 Million CNY | -14.75% |
| 2015 Q2 | 112.08 Million CNY | 40.9% |
| 2015 Q1 | 79.55 Million CNY | -15.87% |
| 2014 Q1 | 80.18 Million CNY | 0.0% |
| 2014 Q4 | 94.55 Million CNY | 0.55% |
| 2014 Q3 | 94.03 Million CNY | -2.68% |
| 2014 Q2 | 96.62 Million CNY | 20.5% |
| 2014 FY | 365.39 Million CNY | 47.55% |
| 2013 FY | 247.64 Million CNY | 8.92% |
| 2012 FY | 227.35 Million CNY | 23.95% |
| 2011 FY | 183.42 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 13.4 Billion CNY | 79.379% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion CNY | 62.556% |
| Dirui Industrial Co.,Ltd. | 1.36 Billion CNY | -102.807% |
| Beijing Strong Biotechnologies, Inc. | 1.74 Billion CNY | -58.755% |
| Medicalsystem Biotechnology Co., Ltd. | 1.88 Billion CNY | -46.612% |
| Maccura Biotechnology Co.Ltd | 2.89 Billion CNY | 4.519% |
| Guangdong Hybribio Biotech Co.,Ltd. | 1.1 Billion CNY | -150.342% |
| BGI Genomics Co., Ltd. | 4.34 Billion CNY | 36.433% |
| Amoy Diagnostics Co., Ltd. | 1.03 Billion CNY | -166.155% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1.67 Billion CNY | -65.132% |